MMP2 and prostate carcinoma: Interaction between CCR1 and CCL5 promotes the invasion of taxane-resistant PC3 prostate cancer cells by increasing the secretion of MMP-2 and -9 via ERK and Rac activation [27] suggesting that CCR1 could be a novel therapeutic target for taxane-resistant prostate cancer.